Successful treatment of a mycophenolate mofetil-refractory proliferative lupus nephritis with Belimumab in a 19-year-old woman.

Abstract

We report the case of a 19-year-old woman with progressive proliferative lupus nephritis (LN) class III after induction and maintenance therapy with mycophenolate mofetil (MMF). Despite a satisfying clinical improvement proteinuria progressed under this medication. We treated the patient with additional belimumab after discussing other options. Following treatment with belimumab, proteinuria rapidly improved to almost normal levels and clinical remission lasted. Belimumab might hold promise for this indication.

• Authors: E E Fließer, P Korsten, M J Koziolek, T B Niewold, D Patschan, G A Müller, S A Patschan
• Journal: Lupus (Lupus) Vol. 22 Issue 14 Pg. 1523-5 (Dec 2013) ISSN: 1477-0962 [Electronic] England
• PMID: 24014569 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antibodies, Monoclonal, Humanized
• Immunosuppressive Agents
• belimumab
• Mycophenolic Acid

Topics

• Antibodies, Monoclonal, Humanized (therapeutic use)
• Disease Progression
• Female
• Humans
• Immunosuppressive Agents (therapeutic use)
• Lupus Nephritis (drug therapy, physiopathology)
• Mycophenolic Acid (analogs & derivatives, therapeutic use)
• Proteinuria (drug therapy, etiology)
• Remission Induction
• Treatment Outcome
• Young Adult